Effects of combination treatment with policosanol and omega-3 fatty acids on platelet aggregation: A randomized, double-blind clinical study

Current Therapeutic Research - Clinical and Experimental

Volumn 67, Issue 3, 2006, Pages 174-192

  Castaño, Gladys ^a   Arruzazabala, Maria L ^b   Fernández, Lilia ^b   Mas, Rosa ^b   Carbajal, Daisy ^b   Molina, Vivian ^b   Illnait, José ^a   Mendoza, Sarahí ^a   Gámez, Rafael ^a   Mesa, Melbis ^a   Fernández, Julio ^b  

^a Medical Surgical Research Center   (Cuba)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

antiplatelet drugs; cholesterol lowering drugs; omega 3 fatty acids; platelet aggregation; policosanol

Indexed keywords

ADRENALIN; ARACHIDONIC ACID; COLLAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CITY; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUBA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEAL; MEDICAL RESEARCH; OUTPATIENT; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEX; THROMBOCYTE AGGREGATION INHIBITION; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL;

EID: 33746021653     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2006.06.004     Document Type: Article

References (69)

1. Wu K.K. Recent advances in hemostatic risk factors and cardiovascular diseases. Fibrinolysis & Proteolysis 11 Suppl 1 (1997) 31-34
2. Murray C.J., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020. Global Burden of Disease Study. Lancet 349 (1997) 1498-1504
3. The Lipid Research Clinics Coronary Primary Prevention. Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251 (1984) 351-364
4. The Lipid Research Clinics Coronary Primary Prevention. Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251 (1984) 365-374
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
6. Sacks F.M., Pfeffer M.A., Moye L.A., et al., Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterollevels. N Engl J Med 339 (1998) 1349-1357
8. Shepherd J., Cobbe S.M., Ford I., et al., West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333 (1995) 1301-1307
9. Downs J.R., Clearfield M., Weis S., et al., Air Force/Texas Coronary Atherosclerosis Prevention Study. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360 (2002) 7-22
11. Shepherd J., Blauw G.J., Murphy M.B., et al., PROSPER Study Group. (PROspective Study of Pravastatin in the Elderly at Risk). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomisedcontrolled trial. Lancet 360 (2002) 1623-1630
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
13. Gotto Jr. A.M., Assmann G., Carmena R., et al. The ILIB Lipid Handbook for Clinical Practice: Blood Lipids and Coronary Heart Disease. 2nd ed (2000), International Lipid Information Bureau, New York, NY
14. Falk E., and Fernandez-Ortiz A. Role of thrombosis in atherosclerosis and its complications. Am J Cardiol 75 (1995) 3B-11B
15. Schafer A.I. Antiplatelet therapy. Am J Med 101 (1996) 199-209
16. Haller H. Endothelial function. General considerations. Drugs 53 Suppl 1 (1997) 1-10
17. Luscher T.F., and Barton M. Biology of the endothelium. Clin Cardiol 20 Suppl 2 (1997) 113-1110
18. Shah P.K. Plaque disruption and coronary thrombosis: New insight into pathogenesis and prevention. Clin Cardiol. 20 Suppl 12 (1997) 1138-1144
19. [published correction appears in BMJ. 1994;308:1540]. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction and stroke by prolongedantiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
20. Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J 19 Suppl A (1998) A12-A19
21. Hassan M., and Amonkar M. Aspirin use for primary and secondary prophylaxis of cardiovascular disease. Curr Ther Res Clin Exp 62 (2001) 676-690
22. Patrono C., Coller B., Dalen J.E., et al. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest 119 Suppl 1 (2001) 39S-63S
23. Mas R. Policosanol. Drugs of the Future 25 (2000) 569-586
24. Ortensi G., Gladstein J., Valli H., and Tesone P.A. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res Clin Exp 58 (1997) 390-401
25. Mas R., Castano G., Illnait J., et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 65 (1999) 439-447
26. Castano G., Mas R., Arruzazabala M.L., et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Cl in Pharmacol Res 19 (1999) 105-116
27. Castano G., Mas R., Fernandez L., et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 14 (2000) 187-195
28. Mas R., Castano G., Fernandez L., et al. Effects of policosanol on lipid profile and cardiac events in older hypercholesterolaemic patients with coronary disease. Clin Drug Invest 21 (2001) 485-497
29. Castano G., Mas R., Fernandez L., et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging 20 (2003) 153-163
30. Torres O., Agramonte A.J., Illnait J., et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 18 (1995) 393-397
31. Crespo N., Illnait J., Mas R., et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependentdiabetes mellitus. Int J Clin Pharmacol Res 19 (1999) 117-127
32. Castano G., Fernandez L., Mas R., et al. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2diabetes mellitus. Clin Drug Invest 23 (2003) 639-650
33. Menendez R., Fernandez S.I., Del Rio A., et al. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 27 (1994) 199-203
34. Menendez R., Arruzazabala M.L., Mas R., et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr 77 (1997) 923-932
35. Menendez R., Amor A.M., Rodeiro I., et al. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res 32 (2001) 8-12
36. Arruzazabala M.L., Valdes S., Mas R., et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res 34 (1996) 181-185
37. Arruzazabala M.L., Mas R., Molina V., et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Int J Tissue React 20 (1998) 119-124
38. Menendez R., Mas R., Amor A.M., et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 50 (2000) 255-262
39. Menendez R., Mas R., Amor A.M., et al. Effects of policosanol on the susceptibility of low-density lipoprotein isolated from hypercholesterolemic patients at high coronary risk to invitro copper-mediated lipid peroxidation: A randomized, double-blind pilot study. Curr Ther Res Clin Exp 61 (2000) 609-620
40. Gamez R., Aleman C.L., Mas R., et al. A 6-month study on the toxicity of high doses of policosanol orally administered to Sprague-Dawley rats. J Med Food 4 (2001) 57-65
41. Mesa A.R., Mas R., Noa M., et al. Toxicity of policosanol in beagle dogs: One-year study. Toxicol Lett 73 (1994) 81-90
42. Rodriguez M.D., and Garcia H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutagen 14 (1994) 107-113
43. Aleman C.L., Mas Ferreiro R., Noa Puig M., et al. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 month study. Teratog Carcinog Mutagen 14 (1994) 239-249
44. Fernandez L., Mas R., Illnait J., and Fernandez J.C. Policosanol: Results of a postmarketing surveillance study of 27,879 patients. Curr Ther Res Clin Exp 59 (1998) 717-722
45. Mas R., Rivas P., Izquierdo J.E., et al. Pharmacoepidemiologic study of policosanol. Curr Ther Res Clin Exp 60 (1999) 458-467
46. Harris W.S., Park Y., and Isley W.L. Cardiovascular disease and long-chain omega-3 fatty acids. Curr Opin Lipidol 14 (2003) 9-14
47. Lee K.W., and Lip G.Y. The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease. QJM 96 (2003) 465-480
48. Richter W.O. Long-chain omega-3 fatty acids from fish reduce sudden cardiac death in patients with coronary heart disease. Eur J Med Res 8 (2003) 332-336
49. Lemaitre R.N., King I.B., Mozaffarian D., et al. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: The Cardiovascular Health Study. Am J Clin Nutr 77 (2003) 319-325
50. Oh R. Practical applications of fish oil (omega-3 fatty acids) in primary care. J Am Board Fam Pract 18 (2005) 28-36
51. [published corrections appear in Am Heart J. 2004;147:IN1 and Am Heart J 2004;147:874]. De Caterina R., Madonna R., Zucchi R., and La Rovere M.T. Antiarrhythmic effects of omega-3 fatty acids: From epidemiology to bedside. Am Heart J 146 (2003) 420-430
52. Mori T.A., and Beilin L.J. Long-chain omega 3 fatty acids, blood lipids and cardiovascular risk reduction. Curr Opin Lipidol 12 (2001) 11-17
53. Gamez R., Maz R., Arruzazabala M.L., et al. Effects of concurrent therapy with policosanol and omega-3 fatty acids on lipid profile and platelet aggregation of rabbits. Drugs R D 6 (2005) 11-19
54. Castano G., Fernandez L., Mas R., et al. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia. Drugs R D 6 (2005) 207-219
55. Schectman G., and Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med 100 (1996) 197-204
56. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 (1981) 239-245
57. Born G.V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194 (1962) 927-929
58. Seigler L., and Wu W.T. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate andmagnesium chloride. Clin Chem 27 (1981) 838-841
59. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultra-centrifuge. Clin Chem 18 (1972) 499-502
60. Din J.N., Newby D.E., and Flapan A.D. Omega 3 fatty acids and cardiovascular disease-fishing for a natural treatment. BMJ 328 (2004) 30-35
61. Masley S.C. Dietary therapy for preventing and treating coronary artery disease. Am Fam Physician 57 (1998) 1299-1306
62. Mori T.A., Beilin L.J., Burke V., et al. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 17 (1997) 279-286
63. Agren J.J., Vaisanen S., Hanninen O., et al. Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation. Prostaglandins Leukot Essent Fatty Acids 57 (1997) 419-421
64. Winther K., Myrup B., Holmer G., et al. Decreased platelet activity without change in fibrinolytic activity after low dosages of fish oil. Angiology 44 (1993) 39-44
65. von Schacky C., Fischer S., and Weber P.C. Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest 76 (1985) 1626-1631
66. von Schacky C., and Weber P.C. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 76 (1985) 2446-2450
67. [in Spanish]. Arruzazabala M.L., Carbajal D., Molina V., et al. Pharmacological study of the interaction between policosanol and aspirin in experimentation animals. Rev Iberoam Tromb Hemost 5 (1992) 17-20
68. Arruzazabala M.L., Molina V., Carbajal D., et al. Effect of policosanol on cerebral ischemia in Mongolian gerbils: Role of prostacyclin and thromboxane A2. Prostaglandins Leukot Essent Fatty Acids 49 (1993) 695-697
69. Carbajal D., Arruzazabala M.L., Valdes S., and Mas R. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostaglandins Leukot Essent Fatty Acids 58 (1998) 61-64